Our experiments revealed that in humanized mouse tumor models, nivolumab and anti-IL-6 antibody alone as well as the combination of nivolumab and anti-IL-6 antibody inhibited the growth of mouse tumors, but the combination treatment was more effective in controlling tumor growth (Figures 8D, E) and improved mouse survival. Here, IL6 is linked to neoplasm.